BiotechTube

Aspirin + Alpha lipoic acid + Olmesartan + Placebo

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Impaired Glucose Tolerance

Conditions

Impaired Glucose Tolerance, Prediabetic State

Trial Timeline

May 1, 2005 → May 1, 2011

NCT ID
NCT00122447

About Aspirin + Alpha lipoic acid + Olmesartan + Placebo

Aspirin + Alpha lipoic acid + Olmesartan + Placebo is a pre-clinical stage product being developed by Daiichi Sankyo for Impaired Glucose Tolerance. The current trial status is completed. This product is registered under clinical trial identifier NCT00122447. Target conditions include Impaired Glucose Tolerance, Prediabetic State.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT00122447Pre-clinicalCompleted

Competing Products

19 competing products in Impaired Glucose Tolerance

See all competitors
ProductCompanyStageHype Score
ASP8825Astellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
GilteritinibAstellas PharmaPhase 1
33
fospropofol + fospropofol + fospropofol + fospropofolEisaiPre-clinical
23
Exenatide + MetforminEli LillyApproved
85
Apatinib MesylateJiangsu Hengrui MedicinePhase 1
33
balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg + balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg + dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozinAstraZenecaPhase 3
77
Tetanus & Diphtheria booster vaccine (Td) + TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine] + Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)MerckPre-clinical
23
ASA404NovartisPhase 1
33
MAS825 + Standard of Care (SoC)NovartisPhase 2
52
DFV890 + Standard of Care (SoC)NovartisPhase 2
52
Immediate switch to TDF/FTC/RPV + Switch to TDF/FTC/RPV after 24 weeksGilead SciencesApproved
84
Gabapentin + Gabapentin + Gabapentin + GabapentinPfizerApproved
84
Ramipril + RosiglitazonePfizerPhase 3
76
HSK7653 10mg Q2W + HSK7653 25mg Q2W + PlaceboHaisco Pharmaceutical GroupPhase 2
49
NBI-98854 50 mg capsuleNeurocrine BiosciencesPhase 1
30
BIS-001ERSupernus PharmaceuticalsPhase 1/2
36
GFT505 80mg + PlaceboGenfitPhase 2
44

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85